370 related articles for article (PubMed ID: 35770982)
1. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
[TBL] [Abstract][Full Text] [Related]
2. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
[TBL] [Abstract][Full Text] [Related]
3. Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan.
Hiramoto S; Miyashita D; Kimura T; Niwa T; Uchida A; Sano M; Murata M; Nagasawa T; Tsunekawa K; Aoki T; Yoshida A; Kato T; Yanagisawa K; Tokue Y; Murakami M
Tohoku J Exp Med; 2022 May; 257(1):57-64. PubMed ID: 35354694
[TBL] [Abstract][Full Text] [Related]
4. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
Plumb ID; Fette LM; Tjaden AH; Feldstein L; Saydah S; Ahmed A; Link-Gelles R; Wierzba TF; Berry AA; Friedman-Klabanoff D; Larsen MP; Runyon MS; Ward LM; Santos RP; Ward J; Weintraub WS; Edelstein S; Uschner D
Vaccine; 2023 Apr; 41(15):2596-2604. PubMed ID: 36932031
[TBL] [Abstract][Full Text] [Related]
5. On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination.
Fernandes-Siqueira LO; Ferreira FAP; Sousa BG; Mebus-Antunes NC; Neves-Martins TC; Almeida FCL; Ferreira GC; Salmon D; Wermelinger LS; Da Poian AT
Sci Rep; 2022 Jun; 12(1):10366. PubMed ID: 35725758
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
7. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
9. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
12. Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination.
Bochnia-Bueno L; De Almeida SM; Raboni SM; Adamoski D; Amadeu LLM; Carstensen S; Nogueira MB
Diagn Microbiol Infect Dis; 2022 Mar; 102(3):115597. PubMed ID: 34902621
[TBL] [Abstract][Full Text] [Related]
13. Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
van den Hoogen LL; Smits G; van Hagen CCE; Wong D; Vos ERA; van Boven M; de Melker HE; van Vliet J; Kuijer M; Woudstra L; Wijmenga-Monsuur AJ; GeurtsvanKessel CH; Stoof SP; Reukers D; Wijsman LA; Meijer A; Reusken CBEM; Rots NY; van der Klis FRM; van Binnendijk RS; den Hartog G
Vaccine; 2022 Apr; 40(15):2251-2257. PubMed ID: 35287986
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
16. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
Front Immunol; 2022; 13():892331. PubMed ID: 36003404
[TBL] [Abstract][Full Text] [Related]
18. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
Søgaard OS; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Stærke NB; Iversen K; Fogh K; Bodilsen J; Iversen M; Knudsen LS; Klastrup V; Larsen FD; Andersen SD; Hvidt AK; Andreasen SR; Madsen LW; Lindvig SO; Øvrehus A; Ostrowski SR; Abildgaard C; Matthews C; Jensen TO; Raben D; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Lundgren J;
Clin Microbiol Infect; 2022 Aug; 28(8):1126-1133. PubMed ID: 35283313
[TBL] [Abstract][Full Text] [Related]
19. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity.
Kara Z; Akçin R; Demir AN; Dinç HÖ; Kocazeybek B; Yumuk VD
Obes Facts; 2022; 15(5):648-654. PubMed ID: 35921804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
